3 Years of Liraglutide vs Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals With Prediabetes
February 22, 2017. This randomized, controlled, double-blind trial evaluated the proportion of patients with prediabetes and obesity/overweight treated with liraglutide 3.0 mg vs placebo over a 3-year period to determine time to diabetes onset. Patients (N=2,254) from 191 clinical research sites were randomized 2:1; all were assigned to caloric restriction and increased physical activity. Fifty percent of patients completed the full study; patients who withdrew were not followed after discontinuation. At study end, 2% of patients in the liraglutide group were diagnosed with diabetes compared with 6% of placebo patients. This corresponded to a hazard ratio of 0.21 (95% confidence interval, 0.13-0.34) for diabetes progression with liraglutide. Patients treated with liraglutide also experienced significantly greater weight loss than placebo patients; both groups had similar adverse event profiles.